Synthesis and vasodilative activity of tanshinone IIA derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 16, 2010, Pages 4892-4894

  Bi, Yue Feng ^a   Xu, Hai Wei ^a,b   Liu, Xiao Qing ^a   Zhang, Xiao Juan ^a   Wang, Zhen Ji ^a   Liu, Hong Min ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b Furen Science and Technology Pharmaceutical   (China)

Author keywords

Synthesis; Tanshinone; Vasodilative activity

Indexed keywords

NORADRENALIN; TANSHINONE IIA; TANSHINONE IIA DERIVATIVE; UNCLASSIFIED DRUG; ABIETANE DERIVATIVE; CRYPTOTANSHINONE; PHENANTHRENE DERIVATIVE; TANSHINONE; VASODILATOR AGENT;

ANIMAL TISSUE; AORTA MEDIA; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG HYDROLYSIS; DRUG SYNTHESIS; NONHUMAN; RAT; THORACIC AORTA; VASODILATATION; ANIMAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; SALVIA MILTIORRHIZA; STRUCTURE ACTIVITY RELATION; SYNTHESIS; VASCULAR SMOOTH MUSCLE; WISTAR RAT;

ANIMALS; AORTA, THORACIC; MUSCLE, SMOOTH, VASCULAR; NOREPINEPHRINE; PHENANTHRENES; RATS; RATS, WISTAR; SALVIA MILTIORRHIZA; STRUCTURE-ACTIVITY RELATIONSHIP; VASODILATOR AGENTS; DITERPENES, ABIETANE;

RATTUS NORVEGICUS;

EID: 77955426385     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.06.076     Document Type: Article

References (16)

1. Z.Y. Fang, R. Lin, B.X. Yuan, Y. Liu, and H. Zhang Life Sci. 81 2007 1339
2. G.B. Wu, E.X. Zhou, and D.X. Qing Eur. J. Pharmacol. 617 2009 102
3. G. Honda, Y. Koezuka, and M. Tabata Chem. Pharm. Bull. 36 1988 408
4. V. Brovkovych, E. Stolarczyk, J. Oman, P. Tomboulian, and T. Milinski J. Pharm. Biomed. Anal. 19 1999 135
5. Anonymous, Chin. Med. J. 1977, 3, 224.
6. B.L. Zhao, W. Jiang, and J.W. Hou Biochem. Mol. Biol. Int. 38 1996 1171
7. F. Zhang, X.D. Ma, and H.F. Jin Mod. J. Integr. Trad. Chin. West. Med. 16 2007 1318
8. H. Wang, X.M. Gao, and B.L. Zhang J. Ethnopharmacol. 99 2005 93
9. K.J. Huang, H. Wang, W.Z. Xie, and H.S. Zhang Spectrochim. Acta, Part A 68 2007 1180
10. C.M. Houlihan, C.T. Ho, and S.S. Chang J. Am. Oil Chem. Soc. 62 1985 96
11. W.L. Wu, W.L. Chang, A.R. Lee, H.C. Lin, and M.L. King J. Med. Sci. 6 1985 159
12. J.K. Qin, X.Z. Bu, Y.F. Wang, Z.Y. Du, X.Y. Wang, Z.S. Huang, L. Ma, L.K. An, and L.Q. Gu Chin. Chem. Lett. 16 2005 1451
13. +.
14. A.G. Silva, G. Zapata-Sudo, A.E. Kummerle, C.A.M. Fraga, E.J. Barreiro, and R.T. Sudo Bioorg. Med. Chem. 13 2005 3431
15. J.M. Raimundo, R.T. Sudo, L.B. Pontes, F. Antunes, M.M. Trachez, and G. Zapata-Sudo Eur. J. Pharmacol. 530 2006 117
16. -5 mmol) was greater than 80%, endothelium was deemed to be intact. Removal of functional endothelium was confirmed by the lack of relaxation (<10%) in the presence of acetylcholine. The tested compounds were dissolved in dimethylsulfoxide (DMSO) as stock solution (50 mg/mL). Contrast tests were performed in the presence of DMSO alone, at the same concentrations as those used with the synthesized compounds, in order to check contractile response of aorta rings was not affected. All the results were performed as mean ± the standard error of the mean (SEM). Dose-response curves were used to exhibit different effects of compounds. Differences between different concentrations were considered statistically significant when paired Student's t-test was under the condition of P <0.05.